{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:35:08Z","timestamp":1774571708541,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1008752","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000}}],"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["844369"],"award-info":[{"award-number":["844369"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-20-COVI-0018"],"award-info":[{"award-number":["ANR-20-COVI-0018"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV- 017335"],"award-info":[{"award-number":["INV- 017335"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant Equipe Fondation pour la Recherche M\u00e9dicale","award":["EQU201903007848"],"award-info":[{"award-number":["EQU201903007848"]}]},{"name":"Grant Equipe Fondation pour la Recherche M\u00e9dicale","award":["EQU201903007848"],"award-info":[{"award-number":["EQU201903007848"]}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","award":["Momentum Grant"],"award-info":[{"award-number":["Momentum Grant"]}],"id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-19-CE45-0009-01"],"award-info":[{"award-number":["ANR-19-CE45-0009-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Department of Energy","award":["89233218CNA000001"],"award-info":[{"award-number":["89233218CNA000001"]}]},{"name":"Los Alamos National Laboratory LDRD program"},{"name":"US National Sciences Foundation","award":["PHY-2031756"],"award-info":[{"award-number":["PHY-2031756"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-OD011095 and R01-AI028433"],"award-info":[{"award-number":["R01-OD011095 and R01-AI028433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche Pharmaceutical Research and Early Development"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Repurposed drugs that are safe and immediately available constitute a first line of defense against new viral infections. Despite limited antiviral activity against SARS-CoV-2, several drugs are being tested as medication or as prophylaxis to prevent infection. Using a stochastic model of early phase infection, we evaluate the success of prophylactic treatment with different drug types to prevent viral infection. We find that there exists a critical efficacy that a treatment must reach in order to block viral establishment. Treatment by a combination of drugs reduces the critical efficacy, most effectively by the combination of a drug blocking viral entry into cells and a drug increasing viral clearance. Below the critical efficacy, the risk of infection can nonetheless be reduced. Drugs blocking viral entry into cells or enhancing viral clearance reduce the risk of infection more than drugs that reduce viral production in infected cells. The larger the initial inoculum of infectious virus, the less likely is prevention of an infection. In our model, we find that as long as the viral inoculum is smaller than 10 infectious virus particles, viral infection can be prevented almost certainly with drugs of 90% efficacy (or more). Even when a viral infection cannot be prevented, antivirals delay the time to detectable viral loads. The largest delay of viral infection is achieved by drugs reducing viral production in infected cells. A delay of virus infection flattens the within-host viral dynamic curve, possibly reducing transmission and symptom severity. Thus, antiviral prophylaxis, even with reduced efficacy, could be efficiently used to prevent or alleviate infection in people at high risk.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1008752","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T13:34:38Z","timestamp":1614605678000},"page":"e1008752","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":46,"title":["Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-7237","authenticated-orcid":true,"given":"Peter","family":"Czuppon","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-833X","authenticated-orcid":true,"given":"Florence","family":"D\u00e9barre","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-2429","authenticated-orcid":true,"given":"Antonio","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3796-1601","authenticated-orcid":true,"given":"Olivier","family":"Tenaillon","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-0002","authenticated-orcid":true,"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":true,"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[]},{"given":"Fran\u00e7ois","family":"Blanquart","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"issue":"13","key":"pcbi.1008752.ref001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus\u2013Infected Pneumonia","volume":"382","author":"Q Li","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"pcbi.1008752.ref002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"N Zhu","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pcbi.1008752.ref003","doi-asserted-by":"crossref","unstructured":"Lai S, Bogoch I, Ruktanonchai N, Watts A, Lu X, Yang W, et al. Assessing spread risk of Wuhan novel coronavirus within and beyond China, January-April 2020: a travel network-based modelling study. medRxiv. 2020.","DOI":"10.1101\/2020.02.04.20020479"},{"key":"pcbi.1008752.ref004","article-title":"The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak","author":"M Chinazzi","year":"2020","journal-title":"Science"},{"issue":"5","key":"pcbi.1008752.ref005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"E Dong","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"issue":"6","key":"pcbi.1008752.ref006","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","volume":"20","author":"R Verity","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"pcbi.1008752.ref007","doi-asserted-by":"crossref","unstructured":"Cereda D, Tirani M, Rovida F, Demicheli V, Ajelli M, Poletti P, et al. The early phase of the COVID-19 outbreak in Lombardy, Italy. arXiv:200309320 [q-bio]. 2020.","DOI":"10.1016\/j.epidem.2021.100528"},{"key":"pcbi.1008752.ref008","article-title":"Estimating the burden of SARS-CoV-2 in France","author":"H Salje","year":"2020","journal-title":"Science"},{"key":"pcbi.1008752.ref009","article-title":"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China","author":"JT Wu","year":"2020","journal-title":"Nature Medicine"},{"key":"pcbi.1008752.ref010","doi-asserted-by":"crossref","unstructured":"Hauser A, Counotte MJ, Margossian CC, Konstantinoudis G, Low N, Althaus CL, et al. Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: a modelling study in Hubei, China and northern Italy. medRxiv. 2020.","DOI":"10.1101\/2020.03.04.20031104"},{"issue":"8","key":"pcbi.1008752.ref011","doi-asserted-by":"crossref","DOI":"10.3201\/eid2608.200219","article-title":"Doubling Time of the COVID-19 Epidemic by Province, China","volume":"26","author":"K Muniz-Rodriguez","year":"2020","journal-title":"Emerging Infectious Diseases"},{"key":"pcbi.1008752.ref012","unstructured":"Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College London\u2014COVID-19 reports. 2020; Report 9."},{"key":"pcbi.1008752.ref013","article-title":"Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study","author":"Q Bi","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"issue":"6491","key":"pcbi.1008752.ref014","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb6936","article-title":"Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing","volume":"368","author":"L Ferretti","year":"2020","journal-title":"Science"},{"key":"pcbi.1008752.ref015","doi-asserted-by":"crossref","unstructured":"Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19. medRxiv. 2020.","DOI":"10.1101\/2020.03.03.20029983"},{"key":"pcbi.1008752.ref016","article-title":"Coronavirus puts drug repurposing on the fast track","author":"C Harrison","year":"2020","journal-title":"Nature Biotechnology"},{"issue":"3","key":"pcbi.1008752.ref017","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"G Li","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"issue":"7816","key":"pcbi.1008752.ref018","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"DE Gordon","year":"2020","journal-title":"Nature"},{"issue":"9","key":"pcbi.1008752.ref019","article-title":"Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load","volume":"9","author":"A Gon\u00e7alves","year":"2020","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"pcbi.1008752.ref020","doi-asserted-by":"crossref","unstructured":"Kim KS, Ejima K, Ito Y, Iwanami S, Ohashi H, Koizumi Y, et al. Modelling SARS-CoV-2 Dynamics: Implications for Therapy. medRxiv. 2020.","DOI":"10.1101\/2020.03.23.20040493"},{"issue":"47","key":"pcbi.1008752.ref021","doi-asserted-by":"crossref","first-page":"eabc7112","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response","volume":"6","author":"A Goyal","year":"2020","journal-title":"Science Advances"},{"issue":"5","key":"pcbi.1008752.ref022","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses","volume":"41","author":"S Jiang","year":"2020","journal-title":"Trends in Immunology"},{"key":"pcbi.1008752.ref023","article-title":"Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?","author":"P Pagliano","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"pcbi.1008752.ref024","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/annrheumdis-2020-217367","article-title":"To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic","volume":"79","author":"FR Spinelli","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"pcbi.1008752.ref025","unstructured":"US National Library of Medicine. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world; 2020 (accessed November 12, 2020). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/home."},{"issue":"9518","key":"pcbi.1008752.ref026","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(06)68541-3","article-title":"Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study","volume":"367","author":"J Mermin","year":"2006","journal-title":"The Lancet"},{"issue":"5","key":"pcbi.1008752.ref027","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"pcbi.1008752.ref028","unstructured":"US Food and Drug Administration. List of Emergency Use Authorizations for treatments of COVID-19; 2021 (accessed January 7, 2021). Available from: https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#coviddrugftn1."},{"issue":"6","key":"pcbi.1008752.ref029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1002588","article-title":"Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses","volume":"8","author":"KA Pawelek","year":"2012","journal-title":"PLOS Computational Biology"},{"issue":"45","key":"pcbi.1008752.ref030","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2009.0448","article-title":"Next-generation tools for evolutionary invasion analyses","volume":"7","author":"A Hurford","year":"2010","journal-title":"Journal of the Royal Society Interface"},{"issue":"15","key":"pcbi.1008752.ref031","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore","volume":"323","author":"BE Young","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"pcbi.1008752.ref032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1001058","article-title":"Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions","volume":"7","author":"JE Pearson","year":"2011","journal-title":"PLOS Computational Biology"},{"issue":"2","key":"pcbi.1008752.ref033","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1137\/120876800","article-title":"Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection","volume":"73","author":"JM Conway","year":"2013","journal-title":"SIAM Journal on Applied Mathematics"},{"key":"pcbi.1008752.ref034","doi-asserted-by":"crossref","unstructured":"Ke R, Zitzmann C, Ribeiro RM, Perelson AS. Kinetics of SARS-CoV-2 infection in the human upper and lower respiratory tracts and their relationship with infectiousness. medRxiv. 2020.","DOI":"10.1101\/2020.09.25.20201772"},{"key":"pcbi.1008752.ref035","doi-asserted-by":"crossref","unstructured":"Jones TC, M\u00fchlemann B, Veith T, Biele G, Zuchowski M, Hoffmann J, et al. An analysis of SARS-CoV-2 viral load by patient age. medRxiv. 2020.","DOI":"10.1101\/2020.06.08.20125484"},{"key":"pcbi.1008752.ref036","doi-asserted-by":"crossref","unstructured":"Kissler SM, Fauver JR, Mack C, Tai C, Shiue KY, Kalinich CC, et al. Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing. medRxiv. 2020.","DOI":"10.1101\/2020.10.21.20217042"},{"issue":"7809","key":"pcbi.1008752.ref037","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"R W\u00f6lfel","year":"2020","journal-title":"Nature"},{"issue":"4","key":"pcbi.1008752.ref038","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(20)30113-4","article-title":"Viral load of SARS-CoV-2 in clinical samples","volume":"20","author":"Y Pan","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"issue":"5","key":"pcbi.1008752.ref039","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"X He","year":"2020","journal-title":"Nature Medicine"},{"issue":"5","key":"pcbi.1008752.ref040","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","volume":"20","author":"KKW To","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"pcbi.1008752.ref041","doi-asserted-by":"crossref","unstructured":"Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, et al. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in healthcare workers: results of the CoV-CONTACT prospective cohort. medRxiv. 2020.","DOI":"10.1101\/2020.09.17.20194860"},{"key":"pcbi.1008752.ref042","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-4684-3563-4_3","volume-title":"Comprehensive Virology: Newly Characterized Vertebrate Viruses. Comprehensive Virology","author":"JA Robb","year":"1979"},{"key":"pcbi.1008752.ref043","article-title":"SARS-CoV-2 (COVID-19) by the numbers","volume":"9","author":"YM Bar-On","year":"2020","journal-title":"eLife"},{"issue":"3","key":"pcbi.1008752.ref044","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1348-0421.1976.tb00978.x","article-title":"Mouse Hepatitis Virus (MHV-2)","volume":"20","author":"N Hirano","year":"1976","journal-title":"Japanese Journal of Microbiology"},{"key":"pcbi.1008752.ref045","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","author":"VJ Munster","year":"2020","journal-title":"Nature"},{"issue":"2","key":"pcbi.1008752.ref046","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2006.11.027","article-title":"The intracellular sites of early replication and budding of SARS-coronavirus","volume":"361","author":"S Stertz","year":"2007","journal-title":"Virology"},{"issue":"9","key":"pcbi.1008752.ref047","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1371\/journal.pbio.0060226","article-title":"SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum","volume":"6","author":"K Knoops","year":"2008","journal-title":"PLoS Biol"},{"key":"pcbi.1008752.ref048","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). SARS-CoV-2: Images and B-roll related to the novel coronavirus (SARS-CoV-2, also known as 2019-nCoV) that causes COVID-19.; 2020 (accessed November 5, 2020). Available from: https:\/\/www.flickr.com\/photos\/niaid\/albums\/72157712914621487\/with\/49531042907\/."},{"key":"pcbi.1008752.ref049","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","author":"P Chen","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pcbi.1008752.ref050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/5576","article-title":"Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell\u2013free virions from blood plasma","volume":"5","author":"T Igarashi","year":"1999","journal-title":"Nature Medicine"},{"issue":"1","key":"pcbi.1008752.ref051","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-65860-x","article-title":"Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)","volume":"10","author":"RM Hoffmann","year":"2020","journal-title":"Scientific Reports"},{"issue":"5","key":"pcbi.1008752.ref052","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41591-020-0843-2","article-title":"Respiratory virus shedding in exhaled breath and efficacy of face masks","volume":"26","author":"NHL Leung","year":"2020","journal-title":"Nature Medicine"},{"key":"pcbi.1008752.ref053","doi-asserted-by":"crossref","unstructured":"Lythgoe KA, Hall M, Ferretti L, de Cesare M, MacIntyre-Cockett G, Trebes A, et al. Within-host genomics of SARS-CoV-2. medRxiv. 2020.","DOI":"10.1101\/2020.05.28.118992"},{"issue":"3","key":"pcbi.1008752.ref054","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"TC Chou","year":"2006","journal-title":"Pharmacological Reviews"},{"issue":"3","key":"pcbi.1008752.ref055","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"BL Jilek","year":"2012","journal-title":"Nature Medicine"},{"issue":"15","key":"pcbi.1008752.ref056","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of Influenza A Virus Infection in Humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"Journal of Virology"},{"key":"pcbi.1008752.ref057","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study","volume":"369","author":"S Zheng","year":"2020","journal-title":"BMJ"},{"issue":"15","key":"pcbi.1008752.ref058","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of Influenza A Virus Infection in Humans","volume":"80","author":"P Baccam","year":"2006","journal-title":"Journal of Virology"},{"key":"pcbi.1008752.ref059","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.arcontrol.2020.09.006","article-title":"In-host Mathematical Modelling of COVID-19 in Humans","volume":"50","author":"EA Hernandez-Vargas","year":"2020","journal-title":"Annual Reviews in Control"},{"key":"pcbi.1008752.ref060","doi-asserted-by":"crossref","first-page":"108438","DOI":"10.1016\/j.mbs.2020.108438","article-title":"Modeling the viral dynamics of SARS-CoV-2 infection","volume":"328","author":"S Wang","year":"2020","journal-title":"Mathematical Biosciences"},{"key":"pcbi.1008752.ref061","doi-asserted-by":"crossref","unstructured":"Port JR, Yinda CK, Owusu IO, Holbrook M, Fischer R, Bushmaker T, et al. SARS-CoV-2 disease severity and transmission efficiency is increased for airborne but not fomite exposure in Syrian hamsters. medRxiv. 2020.","DOI":"10.1101\/2020.12.28.424565"},{"issue":"3","key":"pcbi.1008752.ref062","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge","volume":"26","author":"A Pegu","year":"2019","journal-title":"Cell Host & Microbe"},{"issue":"2","key":"pcbi.1008752.ref063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007626","article-title":"Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials","volume":"16","author":"DB Reeves","year":"2020","journal-title":"PLOS Computational Biology"},{"issue":"573","key":"pcbi.1008752.ref064","doi-asserted-by":"crossref","first-page":"eabe2555","DOI":"10.1126\/scitranslmed.abe2555","article-title":"Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2","volume":"12","author":"A Popa","year":"2020","journal-title":"Science Translational Medicine"},{"key":"pcbi.1008752.ref065","doi-asserted-by":"crossref","unstructured":"Baum A, Copin R, Ajithdoss D, Zhou A, Lanza K, Negron N, et al. REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. medRxiv. 2020.","DOI":"10.1101\/2020.08.02.233320"},{"issue":"8","key":"pcbi.1008752.ref066","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cmi.2020.05.019","article-title":"Review of trials currently testing treatment and prevention of COVID-19","volume":"26","author":"PC Fragkou","year":"2020","journal-title":"Clinical Microbiology and Infection"},{"key":"pcbi.1008752.ref067","unstructured":"WHO Solidarity trial consortium, Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19 \u2013interim WHO SOLIDARITY trial results. medRxiv. 2020."},{"issue":"19","key":"pcbi.1008752.ref068","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pcbi.1008752.ref069","doi-asserted-by":"crossref","first-page":"e1006740","DOI":"10.1371\/journal.pcbi.1006740","article-title":"Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis","volume":"15","author":"S Duwal","year":"2019","journal-title":"PLOS Computational Biology"},{"issue":"541","key":"pcbi.1008752.ref070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"TP Sheahan","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"7826","key":"pcbi.1008752.ref071","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41586-020-2558-4","article-title":"Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates","volume":"585","author":"P Maisonnasse","year":"2020","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1008752","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:11:51Z","timestamp":1671437511000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1008752"}},"subtitle":[],"editor":[{"given":"James R.","family":"Faeder","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1008752","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.07.20092965","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}